Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio’s CEO and CFO will present at two New York healthcare investor conferences, with live and archived webcasts for investors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvation Bio (NUVB) will participate in Citi's 2026 Biopharma Back to School Conference and the 2026 Cantor Global Healthcare Conference in New York in September 2026.
Founder, President and CEO David Hung, M.D., and CFO Philippe Sauvage will join fireside chats and one-on-one meetings. Webcasts of both fireside chats, and 90-day archives, will be accessible via the Investor Relations section of Nuvation Bio's website.
Details
News Market Reaction – NUVB
On Sep 3, the first trading day after this news, NUVB closed 2.38% below the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Citi's 2026 Biopharma Back to School Conference – fireside chat on Wednesday, September 9, 2026, at 9:20 a.m. ET in
New York, NY - 2026 Cantor Global Healthcare Conference – fireside chat on Thursday, September 10, 2026, at 1:35 p.m. ET in
New York, NY
Live webcasts of each fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-participate-in-upcoming-investor-conferences-302868074.html
SOURCE Nuvation Bio, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Nuvation Bio (NUVB) present at Citi's 2026 Biopharma Back to School Conference?
Nuvation Bio is scheduled for a fireside chat at Citi's 2026 Biopharma Back to School Conference on Wednesday, September 9, 2026, at 9:20 a.m. ET in New York, NY.
What is the date and time of Nuvation Bio's fireside chat at the 2026 Cantor Global Healthcare Conference?
Nuvation Bio will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:35 p.m. ET in New York, NY.
Who will represent Nuvation Bio (NUVB) at the upcoming investor conferences?
David Hung, M.D., Founder, President and Chief Executive Officer, and Philippe Sauvage, Chief Financial Officer, will take part in fireside chats and one-on-one meetings at both conferences.
How can investors access the Nuvation Bio (NUVB) conference webcasts?
Live webcasts of each Nuvation Bio fireside chat will be available on the company’s Investor Relations section of its website. An archived recording of each event will remain accessible for 90 days following the webcast.